Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple-dose tablet pharmacokinetic study of GRC 17536 in healthy male volunteers
NL-OMON42613Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GRC-17536 in pain, asthma, chronic obstructive pulmonary disease (COPD) and 1 more (4 arms), sponsored by Glenmark Pharmaceuticals SA. Primary endpoint: Pharmacokinetics of GRC 17536 after multiple oral tablet dosing. Started Mar 2015; status: active, not recruiting.
02
Drugs
GRC-17536
03
Conditions
painasthmachronic obstructive pulmonary disease (COPD)cough
Beyond the preview
Go deeper on NL-OMON42613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42613.